A Drug-Centric View of Drug Development: How Drugs Spread from Disease to Disease

PLoS Computational Biology

Volumn 12, Issue 4, 2016, Pages

  Rodriguez Esteban, Raul ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CONTROL; LIFE CYCLE;

CLINICAL TRIAL; DRUG DEVELOPMENT; IS TECHNOLOGIES; NETWORK MODELS; POWER-LAW; THERAPEUTIC POTENTIALS;

TAXONOMIES;

ADALIMUMAB; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; POSACONAZOLE;

ARTICLE; COHORT ANALYSIS; DISEASES; DRUG APPROVAL; DRUG EFFECT; DRUG MARKETING; DRUG RESEARCH; FACTUAL DATABASE; FOOD AND DRUG ADMINISTRATION; HUMAN; OSTEOARTHRITIS; PROGNOSIS; RHEUMATOID ARTHRITIS; TAXONOMY; TREND STUDY; BIOLOGICAL MODEL; BIOLOGY; CLASSIFICATION; CLINICAL TRIAL (TOPIC); DRUG DATABASE; DRUG DEVELOPMENT; DRUG THERAPY; TRENDS;

CLINICAL TRIALS AS TOPIC; COMPUTATIONAL BIOLOGY; DATABASES, PHARMACEUTICAL; DISEASE; DRUG DISCOVERY; DRUG THERAPY; HUMANS; MODELS, BIOLOGICAL;

EID: 84964777717     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004852     Document Type: Article

References (38)

1. Jordan VC, Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2(3):205–213. 12612646
2. Radley DC, Finkelstein SN, Stafford RS, Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021–1026. 16682577
3. Kesselheim AS, Rising health care costs and life-cycle management in the pharmaceutical market. PLoS Med. 2013;10(6):e1001461. doi: 10.1371/journal.pmed.100146123785261
4. Ashburn TT, Thor KB, Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673–683. 15286734
5. Loging W, Rodriguez-Esteban R, Hill J, Freeman T, Miglietta J, Cheminformatic / bioinformatic analysis of large corporate databases: application to drug repurposing. Drug Discov Today. 2011;8(3–4):109–116.
6. Davis AP, Wiegers TC, Roberts PM, King BL, Lay JM, Lennon-Hopkins K, et al. A CTD-Pfizer collaboration: manual curation of 88,000 scientific articles text mined for drug-disease and drug-phenotype interactions. Database (Oxford). 2013;2013:bat080.
7. Dudley JT, Deshpande T, Butte AJ, Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform. 2011;12(4):303–311. doi: 10.1093/bib/bbr01321690101
8. Hu G, Agarwal P, Human disease-drug network based on genomic expression profiles. PLoS One. 2009;4(8):e6536. doi: 10.1371/journal.pone.000653619657382
9. Nacher JC, Schwartz JM, A global view of drug-therapy interactions. BMC Pharmacol. 2008;8:5. doi: 10.1186/1471-2210-8-518318892
10. Dalkic E, Wang X, Wright N, Chan C, Cancer-drug associations: a complex system. PLoS One. 2010;5(4):e10031. doi: 10.1371/journal.pone.001003120368808
11. Zhao XM, Iskar M, Zeller G, Kuhn M, van Noort V, Bork P, Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Comput Biol. 2011;7(12):e1002323. doi: 10.1371/journal.pcbi.100232322219721
12. Hoffmann R, Valencia A, Life cycles of successful genes. Trends Genet. 2003;19(2):79–81. 12547515
13. Pfeiffer T, Hoffmann R, Temporal patterns of genes in scientific publications. Proc Natl Acad Sci U S A. 2007;104(29):12052–12056. 17620606
14. Rzhetsky A, Wajngurt D, Park N, Zheng T, Probing genetic overlap among complex human phenotypes. Proc Natl Acad Sci U S A. 2007;104(28):11694–11699. 17609372
15. Loscalzo J, Kohane I, Barabasi AL, Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol. 2007;3:124. 17625512
16. Li Y, Agarwal P, A pathway-based view of human diseases and disease relationships. PLoS One. 2009;4(2):e4346. doi: 10.1371/journal.pone.000434619194489
17. Linghu B, Snitkin ES, Hu Z, Xia Y, Delisi C, Genome-wide prioritization of disease genes and identification of disease-disease associations from an integrated human functional linkage network. Genome Biol. 2009;10(9):R91. doi: 10.1186/gb-2009-10-9-r9119728866
18. Stegmaier P, Krull M, Voss N, Kel AE, Wingender E, Molecular mechanistic associations of human diseases. BMC Syst Biol. 2010;4:124. doi: 10.1186/1752-0509-4-12420815942
19. Rodriguez-Esteban R, Loging WT, Quantifying the complexity of medical research. Bioinformatics. 2013;29(22):2918–2924. doi: 10.1093/bioinformatics/btt50523995394
20. Bohacek RS, McMartin C, Guida WC, The art and practice of structure-based drug design: a molecular modeling perspective. Med Res Rev. 1996;16(1):3–50. 8788213
21. Lipinski C, Hopkins A, Navigating chemical space for biology and medicine. Nature. 2004;432(7019):855–861. 15602551
22. Glanville J, Zhai W, Berka J, Telman D, Huerta G, Mehta GR, et al. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc Natl Acad Sci U S A. 2009;106(48):20216–20221. doi: 10.1073/pnas.090977510619875695
23. Deng ZL, Du CX, Li X, Hu B, Kuang ZK, Wang R, et al. Exploring the biologically relevant chemical space for drug discovery. J Chem Inf Model. 2013;53(11):2820–2828. doi: 10.1021/ci400432a24125686
24. Berglund L, Andrade J, Odeberg J, Uhlén M, The epitope space of the human proteome. Protein Sci. 2008;17(4):606–613. doi: 10.1110/ps.07334720818359855
25. Munos B, A forensic analysis of drug targets from 2000 through 2012 (2013)Clin Pharmacol Ther. 2013;94(3):407–411. doi: 10.1038/clpt.2013.12623756372
26. Rogers EM, Diffusion of innovations. New York: Free Press, 1995.
27. Tufts Center for the Study of Drug Development. CNS Drugs Take Longer to Develop and Have Lower Success Rates than Other Drugs. November 4, 2014.
28. Cokol M, Rodriguez-Esteban R, Visualizing evolution and impact of biomedical fields. J Biomed Inform. 2008;41(6):1050–1052. doi: 10.1016/j.jbi.2008.05.00218558511
29. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47–53. doi: 10.1001/jama.2009.194320051569
30. Ebrahim S, Sohani ZN, Montoya L, Agarwal A, Thorlund K, Mills EJ, et al. Reanalyses of randomized clinical trial data. JAMA. 2014;312(10):1024–1032. doi: 10.1001/jama.2014.964625203082
31. Arbesman S, Christakis NA, Eurekometrics: analyzing the nature of discovery. PLoS Comput Biol. 2011;7(6):e1002072. doi: 10.1371/journal.pcbi.100207221738456
32. Chiang AP, Butte AJ, Systematic evaluation of drug-disease relationships to identify leads for novel drug uses. Clin Pharmacol Ther. 2009;86(5):507–510. doi: 10.1038/clpt.2009.10319571805
33. Jung K, LePendu P, Chen WS, Iyer SV, Readhead B, Dudley JT, et al. Automated detection of off-label drug use. PLoS One. 2014;9(2):e89324. doi: 10.1371/journal.pone.008932424586689
34. Vos R. Drugs looking for diseases. A descriptive model for the process of innovative drug research with special reference to the development of the beta blockers and the calcium antagonists [dissertation]. Groningen, Netherlands: University of Groningen, 1989.
35. Thomas P, Starlinger J, Vowinkel A, Arzt S, Leser U, GeneView: a comprehensive semantic search engine for PubMed. Nucleic Acids Res. 2012;40(Web Server issue):W585–591. doi: 10.1093/nar/gks56322693219
36. Kuhn M, Szklarczyk D, Pletscher-Frankild S, Blicher TH, von Mering C, Jensen LJ, Bork P, STITCH 4: integration of protein-chemical interactions with user data. Nucleic Acids Res. 2014Jan;42(Database issue):D401–7. doi: 10.1093/nar/gkt120724293645
37. Myung IJ, Tutorial on maximum likelihood estimation. J Math Psychol. 2003;47:90–100.
38. Letunic I, Bork P, Interactive Tree Of Life v2: online annotation and display of phylogenetic trees made easy. Nucleic Acids Res. 2011Jul;39(Web Server issue):W475–8. doi: 10.1093/nar/gkr20121470960